Skip to main content

Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Terminated · NCT06014541

Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

At a glance

Research payments reported, 2025
$813,366
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
29

About the trial

Sponsor
Ionis Pharmaceuticals, Inc.
Dates
Started 2023-10-03; completion 2025-10-07
Results posted
Not yet

The purpose of the study is to prospectively assess longitudinal changes in biomarkers (MECP2, potential biomarkers of target engagement and disease activity) in cerebrospinal fluid (CSF) and blood; characterize longitudinal changes in performance on clinical scales (clinician-reported measures of neurodevelopment and functioning) and caregiver-reported outcome assessments (communication, gastrointestinal, social-emotional-adaptive behavioral measures); evaluate longitudinal changes in caregiver-reported health-related quality-of-life measures; and assess the frequency, type, and severity of seizures over time.

From ClinicalTrials.gov, last updated 2026-04-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ionis Pharmaceuticals, Inc. reported $813,366 in research payments for this study in 2025 (42 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.